Purpose: Furosemide is commonly prescribed in acute kidney injury (AKI). Prior studies have found conflicting findings on whether furosemide modifies the course and outcome of AKI. Methods: Pilot multi-center randomized blinded placebo-controlled trial in adult patients with AKI admitted to three intensive care units. Participants were randomly allocated to furosemide bolus and infusion or 0.9% saline placebo. Primary endpoint was worsening AKI, defined by the RIFLE criteria. Secondary endpoints were kidney recovery, renal replacement therapy (RRT) and adverse events. Results: The trial was terminated after enrollment of 73 participants (37 to furosemide and 36 to placebo). Mean (SD) age was 61.7 (14.3), 79.5% were medical admissions, mean (SD) APACHE II score was 26.6 (7.8), 90.4% received mechanical ventilation and 61.6% received vasoactives. Groups were similar at baseline. No differences were found in the proportion with worsening AKI (43.2% vs. 37.1%, p = 0.6), kidney recovery (29.7% vs. 42.9%, p = 0.3), or RRT (27.0% s. 28.6%, p = 0.8). Adverse events, mostly electrolyte abnormalities, were more common in furosemide-treated patients (p b 0.001). Protocol deviations were common, due often to supplementary furosemide. Conclusions: In this pilot trial, furosemide did not reduce the rate of worsening AKI, improve recovery or reduce RRT; however, was associated with greater electrolyte abnormalities. Trial registration: ClinicalTrials.gov Identifier: NCT00978354 registered September 9, 2014.
Introduction
Acute kidney injury (AKI) is a frequent and increasingly encountered complication of critical illness, with an incremental risk for morbidity and chronic kidney disease (CKD) [1] . Despite investigation of numerous preventative and therapeutic interventions to prevent or facilitate repair and recovery for AKI, few, if any, have proven effective to favorably modify the course or outcome once AKI is established [1] [2] [3] . However, there remain important knowledge gaps in our understanding of the pathophysiology, case-mix identification, and response to interventions commonly used in AKI [4] .
Loop diuretics, most commonly furosemide [5] [6] [7] , are received by an estimated 60-70% of patients with AKI in intensive care unit (ICU) settings, in spite of a contradictory evidence-base on their effectiveness and safety [8] [9] [10] .
Furosemide acts at the medullary thick ascending loop of Henle to inhibit the Na+/K+/2Cl − pump on the luminal cell membrane surface.
Experimental data and small clinical studies have shown AKI increases kidney metabolic demand and oxidative stress [11] , and this may be attenuated by furosemide [12] [13] [14] . Furosemide reduces renal tubular oxygen demand by impairing tubular Na+ reabsorption [14] , and may attenuate ischemia/reperfusion-induced apoptosis and associated gene transcription in AKI [15, 16] . In contrary, recent data have suggested bolus furosemide aimed at augmenting urine output may increase kidney oxidative stress [17] . Small clinical studies have further suggested that furosemide may attenuate the severity or shorten the duration of AKI, and perhaps delay or ameliorate need for renal replacement therapy (RRT); however, findings have been inconsistent and improvements in survival or renal recovery have yet to be confirmed [8] [9] [10] [18] [19] [20] [21] [22] .
There has recently been recognition of the need for greater investment in strategies to improve outcomes in AKI from randomized trials [4, 23, 24] . Arguably, scientific focus should also aim to improve our understanding of common therapies received by patients with AKI, such as furosemide [17] .
Accordingly, we performed a pilot randomized trial in critically ill patients with mild AKI to compare the efficacy and safety of continuous infusions of furosemide or placebo titrated to urine output on the incidence of worsening AKI. We further aimed to address the feasibility of such an approach, including gaining understanding of clinician equipoise for use of furosemide in critically ill patients with AKI.
Materials and methods
Details of the trial protocol were published and registered (ClinicalTrials.gov Identifier: NCT00978354 registered September 14, 2009) [25] . The Human Research Ethics Committee at each site reviewed and approved the study prior to commencement (University of Alberta HREB file #Pro00002230). Written informed consent was obtained from all participants or their legal representatives.
Study design, setting and participants
We performed a pilot randomized, blinded, placebo-controlled trial at three tertiary university-affiliated hospital intensive care units (ICU): General Systems Intensive Care Unit, University of Alberta Hospital (Edmonton, Canada), Intensive Care Unit, Austin Hospital (Melbourne, Australia) and Intensive Care Unit, Princess Alexandra Hospital (Brisbane, Australia).
We screened patients admitted to a study ICU for eligibility. Inclusion Criteria (all patients were required to fulfill the following criteria): 1) evidence of early AKI (RIFLE category -RISK); 2) peripheral or central intravenous catheter and urinary catheter; 3) ≥2 criteria for the systemic inflammatory response syndrome (SIRS) within 24 h of screening; and 4) achieved immediate resuscitation goals, based on the judgment of the most responsible treating physician and including one or more of the following: fluid resuscitation and/or vasoactive therapy to achieve mean arterial pressure (MAP) ≥65 ), end stage kidney disease (ESKD) receiving maintenance dialysis or kidney transplantation; 5) recent RRT during ICU or index hospitalization; 6) recovering AKI, defined as a ≥ 25% or ≥ 44.2 μmol/L decline from peak increase in serum creatinine; 7) acute pulmonary edema mandating urgent furosemide administration or RRT initiation or patient was already receiving a continuous furosemide infusion; 8) moribund status with expected death within 24 h or significant limitations of medical therapy (LOMT); 9) suspected or known allergy to furosemide; and 10) prior enrolment.
Randomization and blinding
Eligible participants were randomly allocated in a 1:1 ratio to furosemide (bolus followed by continuous infusion) or placebo-control (0.9% saline). Computerized random blocks of variable size (4-8) were stratified within each site and by the presence of sepsis. Randomization was performed by an unblinded clinical trial pharmacist using a web-based application through the Epidemiology Coordinating and Research Centre (EPICORE) at the University of Alberta (available at: https://www. epicore.ualberta.ca/home/). This was concealed from study investigators.
Procedures
The furosemide administration protocol was adapted from a prior trial [26] . Each furosemide infusion bag contained 2000 mg of furosemide in 500 mL of 0.9% saline for a final concentration of 4 mg/mL (Item S1). To ensure blinding of investigators and treating clinicians, study infusion bags for furosemide and placebo appeared identical and were identified by a 4-digit coded identifier.
Each participant received a weight-based loading dose of 0.4 mg/kg followed by a continuous infusion commenced at a dose of 0.05 mg/kg/h. Estimated ideal body weight (IBW), based on the formula described by Devine [27] , was used to determine the urine output target (Tables S2-S4 ). The study infusion was titrated to achieve and maintain a target urine output in the range of 1.0-2.0 mL/kg/h. The maximum infusion rate was 0.40 mg/kg/h. Urine output was assessed hourly. The treatment algorithm for titration of the continuous infusion is shown in the Table S5 .
The study infusion was continued for a minimum of 24 h and discontinued if any one of the following events occurred: 1) kidney recovery; 2) decision to start RRT; 3) death; 4) adverse reaction attributed to study intervention; 5) ICU discharge; or 6) a total of 7-days of study drug had been administered.
All other aspects of patient management within the parameters outlined (i.e., methods of fluid resuscitation, choice of fluids, vasoactive therapy, choice of vasoactive therapy) were left to the discretion of the treating ICU team. No additional interventions were performed.
Operational definitions
Acute kidney injury (AKI) -AKI was defined and classified according to the RIFLE criteria (acronym indicating Risk of renal dysfunction; Injury to the kidney; Failure of kidney function; Loss of kidney function; and End-stage kidney disease) [28] . The presence of early AKI was defined by a minimum of RIFLE category -RISK. Renal replacement therapy (RRT) -RRT was defined as any form of extracorporeal kidney support provided to patients with documented AKI. By protocol and in order to minimize the potential bias of clinician discretion on when to initiate RRT, at least one conventional indications for RRT was required to be fulfilled prior to starting RRT (Item S1). Renal recovery -For the trial, renal recovery was defined as the return of serum creatinine to within 10% of baseline levels and a spontaneous urine output ≥1.0 mL/kg/h for a minimum of 24 h and not receiving RRT. Systemic inflammatory response syndrome (SIRS) -To fulfill SIRS, any 2 or more of the SIRS criteria were required to be fulfilled (see Item S1) [29] . Sepsis -The clinical syndrome of sepsis was defined by the presence of suspected or confirmed infection and the presence of ≥2 SIRS criteria.
Endpoints
The primary endpoint was worsening AKI, defined as progression from RIFLE category -RISK to a more severe category of AKI (i.e., RIFLE categories -INJURY or FAILURE or receipt of RRT) in the 7 days following randomization. Pre-specified secondary endpoints compared differences in cumulative fluid balance, serum electrolytes (i.e., potassium, magnesium), acid-base status (i.e., pH, serum bicarbonate), rates of RRT initiation, rates of renal recovery, and hospital mortality between furosemide and placebo groups, respectively.
Statistical analysis
Based on observational data, we conservatively estimated that 60% of critically ill patients with AKI would worsen and progress [30] . We estimated that furosemide would contribute to a 20% absolute reduction in the proportion who progress from RIFLE class -RISK. This required a sample size of 214 patients to provide 80% power (alpha 0.05) [25] .
Statistical analysis was performed using the principle of intentionto-treat. Normally or near normally distributed variables are reported as means with standard deviations (SD) and compared using the ttest. Continuous data that were far from normality were reported as medians with inter-quartile ranges (IQR) and compared using the Mann Whitney U test. Hodge-Lehmann estimate of location shift with its confidence interval was reported along with the Mann Whitney U test's p-value. Categorical data, including the primary endpoint, and need for RRT, renal recovery and hospital mortality, were reported as proportions and compared using Chi-square test. Fisher's Exact test was used when small expected frequencies invalidates the Chi-square test. Multi-variable logistic regression was used to control for confounding due to imbalances in baseline characteristics after randomization.
Role of the funding source
The funder had no role in the design, data collection, data analysis, interpretation or in the writing of the manuscript. The corresponding author (SMB) and biostatistician (IH) had full access to the data.
Results
Between September 1, 2009 and June 2, 2014, we enrolled 73 participants from 3 sites: 37 were randomly allocated to receive furosemide and 36 to placebo (Fig. 1) .
The trial was terminated early due to feasibility of achieving recruitment following two unavoidable enrollment disruptions to trial recruitment and funding limitations. The termination was supported by the Data Safety Monitoring Committee. These disruptions included: 1) secondment of research personnel to bedside clinical duties during pandemic influenza A(H1N1) in October 2009 (6 months); and 2) a North American shortage of furosemide due to generic drug maker Sandoz Canada suspending production in October 2011, along with inability to import furosemide and restricted access imposed by Alberta Health Services (12 months) .
No patients withdrew consent. One patient allocated to the placebo arm did not receive the study intervention. The primary endpoint was available for all 72 participants and included in the final intention-totreat analysis.
Baseline characteristics
The mean (SD) age of enrolled participants was 61.7 (14.3), 16 (21.9%) were female, mean (SD) APACHE II score was 26.6 (7.8), mean (SD) sequential organ failure assessment (SOFA) score was 10.8 (3.7), 58 (79.5%) were medical admissions, 66 (90.4%) were receiving mechanical ventilation and 45 (61.6%) were receiving vasoactive therapy, respectively.
Following randomization, baseline characteristics, acute physiology, laboratory parameters and treatment intensity were comparable between furosemide and placebo groups (Tables 1 and 2 ). Participants allocated to furosemide had more exposure to vancomycin (67.6% vs. 38.9%, p = 0.01).
Processes of care
In the 72 h prior to randomization, 30 patients (41.0%) had been exposed to furosemide (38.9% for furosemide vs. 48.5% for placebo, p = 0.5). Urine output in the 6 h preceding randomization was similar between the furosemide (210 mL [160-505]) and placebo (235 mL [154-443]) groups (p = 0.9). In total, 69.4% had an episode of oliguria (≤0.5 mL/kg/h × 6 h) in the 72 h prior to randomization (77.8% for furosemide vs. 61.1% for placebo, p = 0.3). Cumulative fluid balance in the 24 h prior to randomization was a median (IQR) 2741 mL (1136- There were no significant differences in organ failure scores, hemodynamic profile, or fluid balance between groups during the study intervention (Fig. 2) . While there were no significant differences in serum creatinine and potassium levels during the study intervention, those allocated to furosemide showed higher serum sodium and bicarbonate levels (Fig. 3) .
Similar proportions of patients in furosemide and placebo groups received potassium supplementation in the first 24 h (46.0% vs. 48.6%, p = 1.0) and 48 h (62.5% vs. 60.0%, p = 1.0) after randomization; however, the furosemide group received greater a cumulative dose over the 
Primary and secondary endpoints
There was no statistically significant difference in the primary endpoint of worsening AKI between furosemide and placebo groups (16 [ No statistically significant differences were observed across secondary endpoints, including kidney recovery, RRT utilization, mortality or a composite of RRT and/or mortality (Table 3) . While there was potentially a clinically meaningful difference in cumulative fluid balance (−1081 mL [95% CI, −2697 to 467]), this was not statistically significant. There were no significant between group differences in maximal changes in electrolytes and acid-base status (Table 4) .
Adverse events and protocol deviations
There was no difference in the proportion of patients with adverse events (p = 0.6); however, the incidence rate was higher in those receiving furosemide (p b 0.001) ( Table 5 ). In the furosemide arm, 25 Abbreviations: IQR = intraquartile range; AKI = acute kidney injury; ACEi = ACE inhibitor; ARB = angiotensinogen receptor blocker; NSAID = non-steroidal anti-inflammatory drug; APACHE = Acute Physiology and Chronic Health Evaluation; SOFA = Sequential Organ Failure Assessment. (67.6%) participants had 111 adverse events reported (incidence rate 4.4 events/patient), of which 2 (5.4%) contributed to study intervention discontinuation. In the placebo arm, 22 (61.1%) participants had 57 adverse events reported (incidence rate 2.6 events/patient), of which 1 (2.8%) contributed to study intervention discontinuation. The majority of adverse events were related to occurrence of electrolyte abnormalities in both groups. Protocol deviations were common; however, not significantly different between groups (p = 0.8). The majority were related to deviation in the treatment algorithm. Compared with the furosemide arm, those allocated to placebo were more likely to receive supplementary diuretic therapy (10.8% vs. 30.6% vs. p = 0.046).
Discussion
There is a pathophysiological mechanistic basis for giving low-dose furosemide in early AKI to reduce kidney metabolic work [14] [15] [16] and we hypothesized that it may mitigate worsening AKI and facilitate earlier recovery of kidney function. We tested this hypothesis in a multicenter pilot randomized trial of critically ill patients with early AKI comparing continuous furosemide infusion to placebo-control on the occurrence of worsening AKI [25] .
We found worsening AKI was common in this cohort of critically ill patients with AKI, occurring in 39.7%, but with no difference between the furosemide and placebo-control groups (43.2% vs. 37.1%, p = 0.6), respectively. We did not find any clinically important differences in key secondary endpoints including kidney recovery, duration of AKI, or mortality. RRT use was also frequent, initiated in 27.4% of patients; however, we found no differences between furosemide and placebotreated groups. A substantial number of adverse events occurred, predominantly attributable to minor electrolyte imbalances, with rates higher among those receiving furosemide. Similarly, protocol deviations frequently occurred in both groups. These were largely due to non-adherence to the study algorithm and extra (i.e., non-protocol) furosemide use.
Context with prior literature
The necessity for additional clinical trials specifically focused on unraveling the optimal use, efficacy and safety of furosemide in AKI stems from an apparent disconnect in the widespread utilization of furosemide in practice juxtaposed with evidence suggestive of no clinical benefit and potential harm [5, [31] [32] [33] . Early clinical trials of furosemide use in AKI were small, confounded by co-interventions (i.e., mannitol, dopamine), characterized by late administration (i.e., long durations of oliguria or already receiving RRT), and by use of large bolus furosemide doses with no specific titration of therapy to physiologic endpoints such as urine output [8] . Such data lack generalizability to AKI and current furosemide practices in ICU settings.
Observational studies detailing the risk of furosemide for development of AKI or poor outcome associated with its use are almost certainly susceptible to confounding by indication [5, 33] . In these studies, the risk of death or non-recovery was predominantly borne by patients with more severe oliguric AKI who did not show a robust response to initial diuretic challenge [5, 33] . It is likely many of these patients had delay to timely start of RRT or had unmeasured differences in probability of being offered RRT. Consistent with the findings of our pilot trial, additional observational studies have not shown significant differences in outcomes associated with furosemide exposure and have failed to confirm any specific incremental risk with furosemide use in AKI [6, 7, 34] .
Indeed, in a cohort of acute lung injured patients with concomitant AKI, after adjusting for fluid balance, there was no ceiling dose of furosemide above which mortality was shown to increase [34] .
While our pilot trial was clearly underpowered and we did not show furosemide reduced the severity or shortened the duration of AKI, furosemide may still have an important role for managing fluid balance and to counterbalance the obligatory fluid intake and optimal delivery of nutrition routinely given to critically ill AKI patients [35, 36] . Moreover, loop diuretics such as furosemide are a common strategy used by clinicians to avert starting RRT among those with severe AKI [37, 38] . However, it remains uncertain whether furosemide exposure in this context portends risk or benefit for kidney recovery or mortality.
Implications for clinicians and research
Despite survey data suggesting clinicians had sufficient equipoise to enroll AKI patients in such a trial, we found this protocol was challenging to implement [39, 40] . Moreover, our data suggested a continuous furosemide infusion is not likely to prevent worsening AKI; however, it may still represent an important approach to maintaining fluid homeostasis. Clinicians appeared concerned about patient fluid status with numerous occurrences of non-protocol administration of furosemide [35] . We believe these observations align with recent data showing diuretic therapy did not confer incremental risk of death or non-recovery in selected critically ill patients when aimed at mitigating fluid accumulation and complications of fluid overload [6, 34] . Furosemide use in ICU settings is predominantly triggered in response to fluid accumulation in the Renal recovery -the operational definition of renal recovery will be the return of serum creatinine to within 10% of baseline levels and a spontaneous urine output ≥1.0 mL/kg/h for a minimum of 24 h independent of RRT.
context of secondary organ injury (i.e., acute lung injury) rather than isolated AKI per se [40] . More recently, the urine output response to a bolus dose of furosemide (i.e., furosemide stress test [FST] ) has shown utility as a functional dynamic measure to predict AKI severity [41, 42] . In critically ill patients with AKI, non-response to a furosemide challenge may represent a logical prompt for support escalation and starting RRT [36, 43] . Future research should focus on the ideal interventional strategies for fluid balance management incorporating the use loop diuretics among critically ill patients with AKI [36] .
Strengths and limitations
Our study had a number of strengths, including being multi-centric, randomized, placebo-controlled, obtaining complete ascertainment of primary endpoints and evaluating a biologically plausible and titratable approach to furosemide administration in critically ill patients with AKI [25] . However, our trial also has noteworthy limitations. Our trial was small and was prematurely terminated, and as such, is predisposed to type I error and has suboptimal statistical power. In addition, we experienced a high rate of protocol deviations, highlighting the challenges with a trial of furosemide administration in critically ill patients. Finally, while allocation was concealed and the intervention blinded, it is plausible that unblinding may have occurred in selected patients with brisk urine output responses to receiving furosemide; however, our primary outcome was objectively measured and analysts were blinded to group assignment.
Conclusions
In summary, in this pilot study, furosemide infusion in critically ill patients with early AKI did not reduce the incidence of worsening AKI or favorably impact any secondary endpoints including kidney recovery, duration of AKI, cumulative fluid balance, RRT use or mortality. In the ICU setting, further research should aim to evaluate the ideal contribution for furosemide in the routine management of critically ill patients with AKI, such as maintaining fluid balance homeostasis. 
